ClinicalTrials.gg
CompletedNCT05502432Updated Aug 16, 2022

Repetitive Transcranial Magnetic Stimulation in SCA3 Patients

An interventional study of Active repetitive transcranial magnetic stimulation and Sham repetitive transcranial magnetic stimulation in Spinocerebellar Ataxia Type 3, sponsored by Ning Wang, MD., PhD.. Completed at 1 site in China. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-08-16.

Sponsored by Ning Wang, MD., PhD. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Dec 2018, registered Sep 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
39
Allocation
Randomized
Ages
20 Years to 80 Years
Sex
All
01

Study summary

Machado-Joseph Disease (MJD) or spinocerebellar ataxia type 3 (SCA3) is the most common spinocerebellar ataxia worldwide.Repetitive transcranial magnetic stimulation (rTMS) is a form of brain stimulation therapy used to treat depression and cerebellar ataxias. In this randomized, double-blind, sham-controlled study, the investigators will evaluate whether a 15 day treatment with 1 Hz of repetitive transcranial magnetic stimulation (rTMS) can improve symptoms (motor symptoms and non-motor symptoms) in patients with MJD.

Read the detailed description

Machado-Joseph Disease (MJD) or spinocerebellar ataxia type 3 (SCA3) is the most common spinocerebellar ataxia worldwide. MJD shows remarked clinical heterogeneity and presents with various clinical manifestations, including cerebellar ataxia, limb incoordination, dysarthria, sleep disorders, axonal neuropathy, dystonia, pyramidal signs and, diplopia. No effective treatment is currently available for MJD.

Repetitive transcranial magnetic stimulation (rTMS)enables non-invasive modulation of cortical excitability. rTMS targeting cerebellar structures is capable of inducing long-lasting changes in the excitability of cerebello-thalamocortical pathways.

Subjects will be randomized in two groups, one receiving a consecutive 15-day treatment with 1 Hz of repetitive transcranial magnetic stimulation and the other receiving sham stimulation with identical parameters. Patients will be clinically assessed at baseline, during intervention period at 7 days and 15 days immediate after treatment.

02

Conditions studied

  • Spinocerebellar Ataxia Type 3

Browse trials for

Keywords

  • Device:Active repetitive transcranial magnetic stimulation
  • Device:Sham repetitive transcranial magnetic stimulation
03

In context

Machado-Joseph Disease

33 studies on the registry are indexed under Machado-Joseph Disease; 5 are open to participants now.

This study's enrollment of 39 is above the median of 23 across 21 interventional studies indexed under Machado-Joseph Disease.

Browse Machado-Joseph Disease studies →

Lead sponsor

Ning Wang, MD., PhD. is the lead sponsor of 9 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1 .Patients with detectable clinical signs and confirmed genetic diagnosis with SCA3.

  1. SCA3 patients aged 20 - 80 years 3. Patients or their family members have to the study and signed relevant documents

Exclusion criteria

Exclusion Criteria:

    1. Patients who have concomitant epilepsy. 2. History of seizure or heat convulsion. 3. Patients on neuroleptics. 4. History or current unstable hypertension. 5. History of head injury or neurosurgical interventions. 6. History of any metal in the head (outside the mouth). 7. Known history of any metallic particles in the eye, implanted cardiac pacemaker, implanted neurostimulators, surgical clips (above the shoulder line) or any medical pumps.

      1. History of frequent or severe headaches. 9. History of migraine. 10. History of hearing loss. 11. History of cochlear implants 12. History of drug abuse or alcoholism. 13. Pregnancy or not using a reliable method of . 14. Participation in current clinical study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
39 participants (actual)

Study arms

  • Active comparator
    Active Repetitive Transcranial Magnetic Stimulation(rTMS)

    15 days with 1 Hz of repetitive transcranial magnetic stimulation (rTMS) with active mood.

    Device: Active repetitive transcranial magnetic stimulation

  • Sham comparator
    Sham Repetitive Transcranial Magnetic Stimulation(rTMS)

    15 days with 1 Hz of repetitive transcranial magnetic stimulation (rTMS) with sham mood.

    Device: Sham repetitive transcranial magnetic stimulation

Interventions

  • DeviceActive repetitive transcranial magnetic stimulation

    Consecutive 15-day active treatment with 1 Hz of repetitive transcranial magnetic stimulation

  • DeviceSham repetitive transcranial magnetic stimulation

    Consecutive 15-day sham treatment with 1 Hz of repetitive transcranial magnetic stimulation

06

What researchers measure

Primary outcomes

  1. ICARS

    The International Cooperative Ataxia Rating Scale (ICARS)

    Time frame: At baseline, during intervention period at 7 days and 15 days immediate after treatment.

Secondary outcomes

  1. BBS

    Berg Balance Scale (BBS)

    Time frame: At baseline, during intervention period at 7 days and 15 days immediate after treatment

  2. SARA

    Scale for the Assessment and Rating of Ataxia (SARA)

    Time frame: At baseline, during intervention period at 7 days and 15 days immediate after treatment

Other outcomes

  1. Tandem gait

    Tandem gait is a gait (method of walking or running) where the toes of the back foot touch the heel of the front foot at each step.

    Time frame: At baseline, during intervention period at 7 days and 15 days immediate after treatment

  2. 10 Metre Walk Test

    The 10 Metre Walk Test is a performance measure used to assess walking speed in metres per second over a short distance. It can be employed to determine functional mobility, gait, and vestibular function.

    Time frame: At baseline, during intervention period at 7 days and 15 days immediate after treatment

  3. Static Stability Test

    Static Stability Test is a objective test use Pro-kin machine to evaluate patient's standing balance.

    Time frame: At baseline and 15 days immediate after treatment

  4. Pittsburgh Sleep Quality Index (PSQI)

    The Pittsburgh Sleep Quality Index (PSQI) is the most commonly used instrument to assess the subjective sleep quality of adults in clinical and community settings

    Time frame: At baseline and 15 days immediate after treatment

  5. Athens Insomnia Scale (AIS)

    The AIS is a self-reported questionnaire designed to measure the severity of insomnia based on the diagnostic criteria of the International Classification of Diseases, 10th revision (ICD-10).

    Time frame: At baseline and 15 days immediate after treatment

  6. Mini-Mental State Examination (MMSE)

    In addressing cognitive screening tools, the MMSE and the MoCA are the most commonly used methods in cognitive impairment detection in both clinical and research fields.

    Time frame: At baseline and 15 days immediate after treatment

  7. Montreal Cognitive Assessment (MoCA)

    In addressing cognitive screening tools, the MMSE and the MoCA are the most commonly used methods in cognitive impairment detection in both clinical and research fields.

    Time frame: At baseline and 15 days immediate after treatmen

  8. Hamilton Anxiety Scale (HAMA)

    HAMA contains 14 questions; each question includes 5 items. Responses are scored as 0 (never), 1 (mild), 2 (moderate), 3 (severe), or 4 (extremely serious). The total score of HAMA is operationally categorized as follows: no anxiety (score 0-6), mild and moderate anxiety (score 7-13), severe anxiety (score ≥ 14).

    Time frame: At baseline and 15 days immediate after treatmen

  9. Hamilton Depression Scale (HAMD)

    HAMD contains 17 questions; each question includes 5 items. Responses are scored as 0 (never), 1 (mild), 2 (moderate), 3 (severe), or 4 (extremely serious). The total score of HAMD can be classified into normal (score 0-6), mild and moderate (score 7-23), severe depression (score ≥ 24).

    Time frame: At baseline and 15 days immediate after treatmen

07

Study locations

1 site
  • Department of Neurology ,First Affiliated Hospital Fujian Medical University
    Fuzhou, Fujian 350005, China
08

References and documents

Publications

  • Shiga Y, Tsuda T, Itoyama Y, Shimizu H, Miyazawa KI, Jin K, Yamazaki T. Transcranial magnetic stimulation alleviates truncal ataxia in spinocerebellar degeneration. J Neurol Neurosurg Psychiatry. 2002 Jan;72(1):124-6. doi: 10.1136/jnnp.72.1.124. No abstract available. PubMed 11784843 ↗
  • Manor B, Greenstein PE, Davila-Perez P, Wakefield S, Zhou J, Pascual-Leone A. Repetitive Transcranial Magnetic Stimulation in Spinocerebellar Ataxia: A Pilot Randomized Controlled Trial. Front Neurol. 2019 Feb 12;10:73. doi: 10.3389/fneur.2019.00073. eCollection 2019. PubMed 30809184 ↗
  • Shimizu H, Tsuda T, Shiga Y, Miyazawa K, Onodera Y, Matsuzaki M, Nakashima I, Furukawa K, Aoki M, Kato H, Yamazaki T, Itoyama Y. Therapeutic efficacy of transcranial magnetic stimulation for hereditary spinocerebellar degeneration. Tohoku J Exp Med. 1999 Nov;189(3):203-11. doi: 10.1620/tjem.189.203. PubMed 10674722 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2018 to primary completion in Oct 2019, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2019
First posted
Aug 16, 2022
StartActual
Dec 17, 2018
Primary completionActual
Oct 1, 2019
CompletionActual
Oct 30, 2019
Last update
Aug 16, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 16, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05502432
Lead sponsor
Ning Wang, MD., PhD.
Responsible party
Ning Wang, MD., PhD. (National Natural Science Foundation of China(U1505222), First Affiliated Hospital of Fujian Medical University) — Sponsor-investigator
First posted
Aug 16, 2022
Start date
Dec 17, 2018
Primary completion
Oct 1, 2019
Completion
Oct 30, 2019
Last update
Aug 16, 2022

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion